The prognostic impact of cytokeratin‐positive cells in bone marrow of patients with localized prostate cancer

Lilleby, Wolfgang; Nesland, Jahn M.; Fosså, Sophie D.; Torlakovic, Goran; Wæhre, Håkon; Kvalheim, Gunnar

doi:10.1002/ijc.10780

Cited by 13 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 In PC, we previously demonstrated in a smaller series that finding of DTCs in BM at least 2 years after definitive external beam RT was associated with clinical progression. 12 However, this study failed to show any clinical prognostic significance of BM-status analyzed before treatment, possibly because of a short time of follow-up.…”

mentioning

confidence: 68%

“…Monitoring of DTCs before and after therapy appears to be of clinical value both in breast cancer 42 and in PC 12 and should therefore be included in future trials. In accordance with the pilot study by Pantel et al 43 showing that the presence of DTCs is reduced during AD, BM should be sampled in PC patients both before and after neoadjuvant AD.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy

Berg

Berner

Lilleby

et al. 2007

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

The purpose of this study was to explore whether detection of disseminated tumor cells (DTCs) in bone marrow (BM) of nonmetastatic prostate cancer (PC) was associated with other clinical or histopathological factors at diagnoses or clinical outcome subsequent to definitive radiotherapy (RT). We evaluated BM aspirates from 272 cT 1-4 pN 0 M 0 PC patients by immunocytochemistry employing anticytokeratin antibodies (AE1/AE3). BM-status was compared with clinical and histopathological parameters. Longterm clinical outcome was assessed in 131 of the patients who all had completed definitive RT with or without androgen deprivation (AD), initiating treatment >5 years before cut-off date June 1, 2005. They had at least 1 unfavorable prognostic feature defined as cT [3][4] or Gleason score (GS) ≥7B or PSA ≥10 lg/l. Overall death, cause-specific death, distant metastases (DM) as first clinical relapse, local failure as first clinical relapse and biochemical failure were defined as end-points. DTCs were detected in 18% of the patients and were associated with increasing GS (p 5 0.04) and percentage of Gleason pattern 4/5 (p 5 0.04). The 7-year cumulative risk of DM was 21% for BM-positive patients vs. 6% for BM-negative patients (p 5 0.07). In patients receiving RT without AD (n 5 75), the 7-year cumulative risk of DM for BM-positive patients was 28% vs. 9% for BM-negative patients (p 5 0.03). BM-status did not have impact on other end-points. In conclusion our study shows that presence of DTCs in BM at diagnosis was associated with the histological differentiation of the primary tumor and an increased risk of developing distant metastases after RT. ' 2007 Wiley-Liss, Inc.

show abstract

mentioning

confidence: 68%

Section: Discussionmentioning

confidence: 99%

Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy

Berg

Berner

Lilleby

et al. 2007

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recently, Lilleby et al (21) reported results from a study of 67 localized PC patients treated with curative radiotherapy. Patients with cytokeratin-positive BM following therapy had a significantly worse outcome than those without any finding in the BM.…”

Section: Immunocytochemistry and Prostate Cancermentioning

confidence: 97%

Old and New Research into Micrometastases in Prostate Cancer

Ogreid

Kvalheim²

2003

Scandinavian Journal of Urology and Nephrology

Self Cite

View full text Add to dashboard Cite

“…Furthermore samples taken after radical prostatectomy or radiotherapy had a lower frequency of micrometastatic detection [153, 155, 156] and that these cells were cytogenetically aberrant [157]. The inference of these findings is either local removal of the primary tumor decreases or eliminates micrometastatic disease, that is to say that the micrometastasis is dependent on a factor produced by the primary tumor in order to survive or the method of detection in some way is deficient or the interpretation of what the test is detecting.…”

Section: Clinical Evidence and Possible Usesmentioning

confidence: 99%

“…Some studies have reported no association with biochemical failure [159, 160], whereas others have reported a higher rate of failure when detected in post-treatment samples [156, 161]. …”

Section: Clinical Evidence and Possible Usesmentioning

confidence: 99%

Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management

Murray

2018

Biol Res

View full text Add to dashboard Cite

Minimal residual disease is that not detected by conventional imaging studies and clinically the patient remains disease free. However, with time these dormant cells will awaken and disease progression occurs, resulting in clinically and radiological detectable metastatic disease. This review addresses the concept of tumor cell dissemination from the primary tumor, the micrometastatic niche and tumor cell survival and finally the clinical utility of detecting and characterizing these tumor cells in order to guide management decisions in treating patients with prostate cancer.

show abstract

The prognostic impact of cytokeratin‐positive cells in bone marrow of patients with localized prostate cancer

Cited by 13 publications

References 33 publications

Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy

Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy

Old and New Research into Micrometastases in Prostate Cancer

Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management

Contact Info

Product

Resources

About